Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial).-MedSci.cn

Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk NMIBC (CATUNIBLA phase I trial).

Albert, F; Antoniewicz, A; Grantzow, T; Fingerle-Rowson, G; Ruf, P; Lindhofer, H; Kriegmair, M; Oberneder, R

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16): E16555

科室
- - 订阅+
  - 更多科室
工具
服务